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SedationOver the last years, genetic studies have greatly improved our knowledge on the receptor subtypes
mediating various pharmacological effects of positive allosteric modulators at GABAA receptors. This
stimulated the development of new benzodiazepine (BZ)-like ligands, especially those inactive/low-active at
GABAA receptors containing the α1 subunit, with the aim of generating more selective drugs. Hereby, the
afﬁnity and efﬁcacy of four recently synthesized BZ site ligands: SH-053-2′N, SH-053-S-CH3-2′F, SH-053-R-
CH3-2′F and JY-XHe-053 were assessed. They were also studied in behavioral tests of spontaneous locomotor
activity, elevated plus maze, and water maze in rats, which are considered predictive of, respectively, the
sedative, anxiolytic, and amnesic inﬂuence of BZs. The novel ligands had moderately low to low afﬁnity and
mild to partial agonistic efﬁcacy at GABAA receptors containing the α1 subunit, with variable, but more
pronounced efﬁcacy at other BZ-sensitive binding sites. While presumably α1 receptor-mediated sedative
effects of GABAA modulation were not fully eliminated with any of the ligands tested, only SH-053-2′N and
SH-053-S-CH3-2′F, both dosed at 30 mg/kg, exerted anxiolytic effects. The lack of clear anxiolytic-like
activity of JY-XHe-053, despite its efﬁcacy at α2- and α3-GABAA receptors, may have been partly connected
with its preferential afﬁnity at α5-GABAA receptors coupled with weak agonist activity at α1-containing
subtypes. The memory impairment in water-maze experiments, generally reported with BZ site agonists,
was completely circumvented with all four ligands. The results suggest that a substantial amount of activity
at α1 GABAA receptors is needed for affecting spatial learning and memory impairments, while much weaker
activity at α1- and α5-GABAA receptors is sufﬁcient for eliciting sedation.t-butyl ester; BZ, benzodiaze-
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The benzodiazepines (BZs) have been widely used for half a
century for several neuropsychiatric disorders. They are positive
allosteric modulators of the BZ binding site at GABAA receptors in thecentral nervous system. This site is located at the interface of anα and
a γ2 subunit of a GABAA receptor usually composed of 1γ and 2α and
2β subunits. BZs act through those populations of GABAA receptors
which contain an α1, α2, α3 or α5 subunit adjacent to the γ2 subunit
(α1 receptors, α2 receptors, etc), and by that exert anxiolytic,
sedative, hypnotic, muscle relaxant, anticonvulsive and amnesic
effects (reviewed in Sieghart and Ernst, 2005). Although the second
α subunit of the receptor might be of the same or a different subunit
type, according to current knowledge it does not play a role in
benzodiazepine pharmacology since it does not form the interface
with the γ2 subunit (Minier and Sigel, 2004).
In regard to the treatment of anxiety disorders, which has been the
most extensive ﬁeld of application of BZs, their continuous use as ﬁrst-
choice anxiolytics has been repeatedly discouraged in the pertinent
guidelines (e.g. Baldwin et al., 2005; Bandelow et al., 2008), mainly
377M.M. Savić et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 34 (2010) 376–386due to untoward effects (most notably, sedation, amnesia, tolerance
and dependence). However, the currently available non-BZ drugs,
preferred for long-term treatment, are also far from completely
meeting the needs imposed on contemporary pharmacotherapy of
anxiety disorders (Garner et al., 2009). On the other hand, the results
of exquisite genetic studies, with mice carrying a point mutation
(‘knock-in’) that changes histidine to arginine in α1, α2, α3 or α5
subunits, which renders the respective GABAA receptors selectively
insensitive to effects of BZ site modulators (Wieland et al., 1992), have
supported the highly desirable possibility of separation of the diverse
behavioral effect of BZs. Principally, the sedative and ataxic effects of
BZs have been attributed to α1-containing GABAA receptor subtypes,
anxiolytic actions to the α2/α3-containing receptors, anterograde
amnesic effects to theα1/α5-subtypes, anticonvulsant activity, in part,
to all the α1/α2/α3 containing receptors, muscle relaxant effects
largely to α2-subtypes, and tolerance to sedative effects to α5-
containing receptors (reviewed in Rudolph and Möhler, 2006). This
has stimulated new interest in the synthesis of novel subtype selective
ligands which act through BZ binding site, aimed to selectively bind
and/or activate speciﬁc GABAA receptor subtype(s) presumably
involved in the desired pharmacological effect (Sieghart and Ernst,
2005; Whiting, 2006). If the concept holds true, an ideal anxioselec-
tive anxiolytic, selectively acting through α2/α3-containing receptors,
would be devoid of sedative, ataxic, amnesic and tolerance adverse
effects. However, despite the notable successes of the studies of
several research groups published to date (reviewed in Whiting,
2006; also Mirza et al., 2008), including the encouraging safety
records for an α2/α3-subtype selective partial modulator in healthy
volunteers (de Haas et al., 2007), it appears that the ultimate goal of
translating breakthroughs in preclinical research into new clinical
therapies is still far from realization. The awareness that a similar
conclusion may apply to the whole ﬁeld of pharmacological
modulation of central nervous system disorders (Markou et al.,
2009) calls for rethinking the clear-cut hypotheses on receptor
subtypes and their roles. In this vein, it is interesting to note that some
newer BZ binding-site agonists, such as ocinaplon (Lippa et al., 2005)
and DOV 51892 (Popik et al., 2006), were reportedly devoid of overt
sedative effects, despite the fact that they did not display compelling
selectivity for either of the GABAA receptor subtypes (cf. Berezhnoy
et al., 2008).
In pursuit of the approach of pharmacological testing of four
subtypes of BZ-sensitive GABAA receptors to further elucidate their
native role, a series of BZ site ligands, presumably inactive/low-active
at α1-containing GABAA receptors, was recently synthesized at the
University of Wisconsin—Milwaukee. Speciﬁc portions of the charac-
terization of six of them, with code names SH-053-S-CH3, SH-053-R-
CH3, SH-053-2′N, JY-XHe-053, SH-053-S-CH3-2′F and SH-053-R-
CH3-2′F, have been already published (Rivas et al., 2009; Savić
et al., 2008a,b). In the present paper, the afﬁnity and efﬁcacy data of
four of these ligands: SH-053-2′N, SH-053-S-CH3-2′F, SH-053-R-CH3-
2′F and JY-XHe-053, as well as their behavioral actions in the tests of
spontaneous locomotor activity, elevated plus maze and water maze,
which are considered primarily predictive of, respectively, the
sedative, anxiolytic, and amnesic inﬂuence of BZs, will be described.
Diazepam, a standard non-selective positive allosteric modulator, and
zolpidem, a moderately α1-subtype selective positive modulator
(Hadingham et al., 1993; Sanna et al., 2002), were used as reference
ligands, where applicable. The aim of the study was to elucidate
whether the expected subtle afﬁnity and efﬁcacy differences at four
BZ-sensitive GABAA receptor subtypes among the tested BZ site
modulators reﬂect themselves in dissimilarities in behavioral
responses of Wistar rats, with possible implications for further
research. Concurrently, the data were to be compared with ﬁndings
from the knock-in approach (reviewed in Rudolph and Möhler, 2006)
as well as with results from classical studies in the same behavioral
tests, investigating antagonism of the effects of non-selective positivemodulators (diazepam or midazolam) with the preferential α1-
subunit afﬁnity-selective antagonist, ß-CCt (Savić et al., 2004, 2009).
2. Experimental procedures
2.1. Drugs
The SH-053-2′N (8-ethynyl-6-(2′-pyrydine)-4H-2,5,10b-triaza-
benzo[e]azulene-3-carboxylic acid ethyl ester), SH-053-S-CH3-2′F
and SH-053-R-CH3-2′F (the (S) and (R) stereoisomer, respectively, of
8-ethynyl-6-(2-ﬂuorophenyl)-4-methyl-4H-2,5,10b-triaza-benzo[e]
azulene-3-carboxylic acid ethyl ester), as well as JY-XHe-053 (8-
ethynyl-6-(2-ﬂuorophenyl)-4H-2,5,10b-triaza-benzo[e]azulene-3-
carboxylic acid ethyl ester) were synthesized at the Department of
Chemistry and Biochemistry, University of Wisconsin—Milwaukee.
Zolpidem for behavioral studies was purchased from Toronto
Research Chemicals (North York, Canada), and diazepam was
obtained from Galenika (Belgrade, Serbia).
2.2. Competition binding assays
Competition binding assays were performed in a total volume of
0.5 mL at 4 °C for 1 h using [3H] ﬂunitrazepam as the radiolabelled
ligand. A total of 6 µg of cloned humanGABAA receptor DNA containing
desired α subtype along with β2 and γ2 subunits were used for
transfecting HEK 293T cell line using Fugene 6 (Roche Diagnostic)
transfecting reagent. Cells were harvested 48 h after transfection,
washed with Tris–HCl buffer (pH 7.0) and Tris Acetate buffer (pH 7.4)
and resulting pellets were stored at−80C until assayed. On the day of
the assay, pellets containing 20–50 μg of GABAA receptor protein were
resuspended in (50 mM Tris–acetate pH 7.4 at 4°) and incubated with
the radiolabel as previously described (Choudhary et al., 1992). Non-
speciﬁc binding was deﬁned as radioactivity bound in the presence of
100 μM diazepam and represented less than 20% of total binding.
Membranes were harvested with a Brandel cell harvester followed by
three ice-coldwashes onto polyethyleneimine-pretreated (0.3%)What-
man GF/C ﬁlters. Filters were dried overnight and then soaked in
Ecoscint A liquid scintillation cocktail (National Diagnostics; Atlanta,
GA). Bound radioactivitywas quantiﬁed by liquid scintillation counting.
Membrane protein concentrations were determined using an assay kit
from Bio-Rad (Hercules, CA) with bovine serum albumin as the
standard.
2.3. Electrophysiological experiments
The cloning of rat GABAA receptor subunits α1, β3 and γ2 into
pCDM8 expression vectors (Invitrogen, CA) has been described
elsewhere (Fuchs et al., 1995). The rat cDNAs for subunits α2, α3 and
α5 were gifts from P. Malherbe and were subcloned into pCI-vector.
After linearizing the cDNA vectors with appropriate restriction
endonucleases, capped transcripts were produced using the mMessage
mMachine T7 transcription kit (Ambion, TX). The capped transcripts
were polyadenylated using yeast poly(A) polymerase (USB, OH) and
were diluted and stored in diethylpyrocarbonate-treated water at
−70 °C.
The methods used for isolating, culturing, injecting and defollicu-
lating of the oocytes were identical as described previously (Sigel,
1987; Sigel et al., 1990). Brieﬂy, mature female Xenopus laevis (Nasco,
WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-
aminobenzoat, Sigma, MO) before decapitation and removal of the
frogs' ovary. Stages 5 to 6 oocytes with the follicle cell layer around
them were singled out of the ovary using a platinum wire loop.
Oocytes were stored and incubated at 18 °C in modiﬁed Barths'
Medium (MB, containing 88 mMNaCl, 10 mMHEPES–NaOH (pH 7.4),
2.4 mM NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, and
0.34 mM Ca(NO3)2) that was supplemented with 100 U/ml penicillin
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themwere injectedwith a total of 2.25 ng of cRNA. cRNA ratio usedwas
1:1:5 for theα subunits,β3 andγ2, respectively. After injection of cRNA,
oocytes were incubated for at least 36 h before the enveloping follicle
cell layers were removed. To this end, oocytes were incubated for
20 min at 37 °C in MB that contained 1 mg/ml collagenase type IA and
0.1 mg/ml trypsin inhibitor I-S (both Sigma). This was followed by
osmotic shrinkage of the oocytes in doubly concentrated MB medium
supplied with 4 mM Na-EGTA and manually removing the follicle cell
layer. After peeling off the follicle cell layer, the cells were allowed to
recover overnight before being used in electrophysiological
experiments.
For electrophysiological recordings, oocyteswere placed on a nylon-
grid in a bath of Xenopus Ringer solution (XR, containing 90 mM NaCl,
5 mMHEPES–NaOH (pH 7.4), 1 mMMgCl2, 1 mMKCl and 1 mMCaCl2).
The oocytes were constantly washed by a ﬂow of 6 ml/min XR which
could be switched to XR containing GABA and/or drugs. Drugs were
diluted into XR from DMSO-solutions resulting in a ﬁnal concentration
of 0.1% DMSO perfusing the oocytes. Drugs were preapplied for 30 s
before the addition of GABA,whichwas coappliedwith the drugs until a
peak response was observed. Between two applications, oocytes were
washed in XR for up to 15 min to ensure full recovery from desensi-
tization. For current measurements the oocytes were impaled with two
microelectrodes (2–3 mΩ) which were ﬁlled with 2 mM KCl. All
recordings were performed at room temperature at a holding potential
of −60 mV using a Warner OC-725C two-electrode voltage clamp
(Warner Instruments, Hamden, CT). Data were digitised, recorded and
measured using a Digidata 1322A data acquisition system (Axon
Instruments, Union City, CA). Results of concentration response
experiments were graphed using GraphPad Prism 4.00 (GraphPad
Software, San Diego, CA). Data were graphed as mean±SEM of at least
four oocytes from at least two batches.
2.4. Behavioral experiments
Experiments were carried out on male Wistar rats (Military Farm,
Belgrade, Serbia), weighing 220–250 g. All procedures in the study
conformed to EEC Directive 86/609 and were approved by the Ethical
Committee on Animal Experimentation of the Faculty of Pharmacy in
Belgrade. The rats were housed in transparent plastic cages, six animals
per cage, and had free access to food pellets and tap water. The
temperature of the animal room was 22±1 °C, the relative humidity
40–70%, the illumination 120 lx, and the12/12 h light/dark period (light
on at 6:00 h). All handling and testing took place during the light phase
of the diurnal cycle. Separate groups of animals were used for three
behavioral paradigms. Care was taken to counterbalance the test order
across treatment conditions. The differences in treatments in individual
paradigms (vide infra) are related to the fact that some pertinent parts
of experiments have been done previously (Savić et al., 2004, 2008b,
2009). The behavior was recorded by a ceiling-mounted camera and
analyzed by the ANY-maze Video Tracking System software (Stoelting
Co., Wood Dale, IL, USA). The drugs were dissolved/suspended with the
aid of sonication in a solvent containing 85% distilled water, 14%
propylene glycol, and 1% Tween 80, and were administered intraper-
itoneally in a volume of 2 ml/kg, 20 min before behavioral testing. The
selection of dose ranges and the injection-test interval was based on
previous experiments (Rivas et al., 2009; Savić et al., 2004, 2008b), as
well as on observations in preliminary experiments, avoiding, where
applicable, testing of lower doses in case of lack of the expected
behavioral effect at a higher dose.
2.5. Measurement of locomotor activity
Twenty minutes after receiving the appropriate treatment, single
rats were placed in a clear Plexiglas chamber (40×25×35 cm). Activity
under dim red light (20 lx)was recorded for a total of 30 min or 45 min,without any habituation period, using ANY-maze software. Besides the
total distance travelled, behavior was analyzed by dividing the
locomotor activity data into 5-min bins. For purposes of improving
data analysis, the central 20%of the chamber (200 cm2)was virtually set
as a central zone. An entry into a zone was counted when 70% of the
animal's body had crossed the zone border. An exit from the zone was
counted when more than 50% of the animal's body had left the zone.
Three experiments were performed. In the ﬁrst study, locomotor
inﬂuences of SH-053-2′N, dosed at 30 mg/kg, were assessed in
comparison with diazepam at 1.25 and 2.5 mg/kg. In the second
experiment, the dose response curve for JY-XHe-053 (0; 2.5; 5; 10; 20
and 40 mg/kg), and in the third, for SH-053-R-CH3-2′F (0; 10; 20 and
30 mg/kg, in comparison with 2 mg/kg diazepam), were determined.
The characterisation of SH-053-S-CH3-2′F in this test has been
published previously (Savić et al., 2008b).
2.6. Behavior in the elevated plus maze
The apparatus was constructed of sheet metal, with a black rubber
ﬂoor. It consisted of amaze elevated to a height of 50 cmwith two open
(50×10 cm) and two enclosed arms (50×10×40 cm), connected by a
junction area (central platform) measured 10×10 cm. A ledge of sheet
metal (0.3 cm high) surrounding the open arms was added. The
illumination in the experimental room consisted of one red neon tube
ﬁxed on the ceiling, giving light intensity of 10 lx on the surface of the
closed arms. At the beginning of the experiment, single rats were placed
in the center of the maze, facing one of the enclosed arms, and their
behavior was recorded for 5 min. An entry into an open or closed arm
was scored when 90% of the animal crossed the virtual line separating
the central square of the maze from the arm, whereas an exit occurred
when more than 90% of the animal left the respective arm. After each
trial, the maze was cleaned with dry and wet towels.
Three experiments were performed, in which the dose response
curves for SH-053-2′N (0; 10; 20 and 30 mg/kg, in comparison with
2.0 mg/kg diazepam), JY-XHe-053 (0; 2.5; 5; 10; 20 and 40 mg/kg),
and SH-053-R-CH3-2′F (0; 10; 20 and 30 mg/kg) were determined.
The characterisation of SH-053-S-CH3-2′F in this test has been
published previously (Savić et al., 2008b).
2.7. Behavior in the Morris water maze
The water maze consisted of a black cylindrical pool (diameter:
200 cm, height: 60 cm),withauniform inner surface. Thepoolwasﬁlled
to a height of 30 cm with 23 °C (±1 °C) water. The escape platform
made of black plastic (15×10 cm) was submerged 2 cm below the
water surface. The platform was made invisible to rats by having it
painted the same color as the pool wall (Terry, 2000). There weremany
distal cues in the testing room (doors, pipes on thewalls and the ceiling,
and cupboards). An indirect illumination in the experimental roomwas
provided by white neon tubes ﬁxed on the walls near the pool.
The rats received the appropriate treatment 20 min before a
swimming block, each day for 5 consecutive days of spatial
acquisition. Each block consisted of 4 trials, lasting a maximum time
of 120 s, the intertrial interval being 60 s. For each trial the rat was
placed in the water facing the pool at one of four pseudorandomly
determined starting positions. As during spatial learning the platform
was hidden in the middle of the NE quadrant, the four distal start
locations were chosen: S, W, NW and SE. Once the rat found and
mounted the escape, it was permitted to remain on the platform for
15 s. The rat was guided to the platform by the experimenter if it did
not locate the escape within 120 s. To assess the long-term spatial
memory at the end of learning, a probe trial for 60 s, with the platform
omitted, was given 24 h after the last acquisition day. The probe trial,
starting from the novel, most distant SW location, was performed
without any pre-treatment. The tracking software virtually divided
the pool into four quadrants, three concentric annuli and a target
Table 1
Binding afﬁnity at αxβ3γ2 GABAA/BZ site subtypes. Measurements were made in
duplicate. Ki values are reported in nM.
Compound α1 α2 α3 α4 α5 α6
Diazepam 14.0 7.8 13.9 NDa 13.4 NDa
Zolpidem 29.6 160.0 380.0 NDa N10000 NDa
SH-053-2′N 300.0 160.0 527.0 NDb 82.0 N5000
SH-053-2′Nc 118.0 148.0 365.0 N5000 77.0 N5000
SH-053-R-CH3-2′F 759.1 948.2 768.8 NDb 95.2 NDb
SH-053-S-CH3-2′F 468.2 33.3 291.5 NDb 19.2 N5000
JY-XHe-053 22.0 12.3 34.9 NDb 0.7 NDb
a ND, not determined.
b Binding at α4 and α6 subtypes have not been determined, but since the 6-phenyl
group is present, the ligand will not bind to α4 and α6 subtypes.
c The second independent set of experiments with SH-053-2′N.
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platform (middle) annulus, as graphically represented in Savić et al.
(2009). The central annulus was set up to 10% of the whole area; the
platform annulus equaled 40%, whereas the area of the peripheral
annulus was 50% of the whole.
Dependent variables chosen for tracking during the acquisition
trials were: latency to platform (time from start to goal), total distance
swam (path length), average swim speed and path efﬁciency (the
ratio of the shortest possible path length to actual path length). All
these indices are, to a lesser or greater degree, related to goal-directed
behavior, i.e. spatial learning (Vorhees and Williams, 2006). As
thigmotaxis (the tendency to swim or ﬂoat near the pool wall)
represents a factor which accounts for much of the variance in the
water-maze performance, and normally weakens during consecutive
trials (Vorhees and Williams, 2006), we quantiﬁed the persistence of
the thigmotaxis in the target (NE) quadrant. The loss of thigmotaxis is
related to the procedural component of acquisition, and the percent of
the distance swum in the target region (away from the wall) of the
target quadrant may be seen as a measure of procedural learning. The
indices of memory, assessed during the probe trial, included the
distance and time in the platform (target) quadrant, platform ring and
target region, as well as the number of entries and distance swum in
the area where the platform used to be during training. In addition,
the distance swum during 60 s in the probe trial was taken as a
measure of overall activity, while peripheral ring parameters
(distance and time) were connected to the thigmotaxic behavior.
Three experiments in the water maze were performed. In the ﬁrst
study, the dose response curve for zolpidem (0; 0.5; 1 and 2 mg/kg)
was found. In the second experiment, water-maze activity of SH-053-
2′N, SH-053-S-CH3-2′F and SH-053-R-CH3-2′F, all dosed at 30 mg/kg,
was assessed. Finally, the inﬂuence of JY-XHe-053 (0; 5; 20 and
40 mg/kg) on the water-maze behavior was determined.
2.8. Statistical analysis
All numerical data presented in the ﬁgures were given as the
mean±SEM. For electrophysiological data Student's t-test was used.
Data sets were checked for homogeneity of variance and normality
prior to analysis by a one-way ANOVA (the activity assay and
elevated plus maze), or a two-way ANOVA with repeated measures
(the water-maze test). Where applicable, Student–Newman–Keuls
or Dunnett's test (post hoc comparisons) and analysis of covariance
were also used. Statistical analyses were performed with ANY-maze
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA)
and SigmaStat 2.0 (SPSS, Inc., Chicago, IL, USA).
3. Results
3.1. Competition binding assays
In vitro binding data for SH-053-2′N, SH-053-S-CH3-2′F, SH-053-
R-CH3-2′F and JY-XHe-053, in parallel with those for diazepam and
zolpidem, are presented in Table 1. Broadly speaking, these ligands
were binding with biologically relevant nanomolar- to micromolar
afﬁnity to the BZ-sensitive recombinant human GABAA receptors,
while were devoid of binding and activity in approximately 40 other
receptor and enzyme assays (NIMH Psychoactive Drug Screening
Program, UNC, available at https://kidbdev.med.unc.edu/pdsp). No
major selectivity in binding at one over the other receptors was
noticed (JY-XHe-053 was the most selective ligand, with approxi-
mately 18-fold selectivity for GABAA receptors containing the α5
subunit, while zolpidem exerted an approximately 5-fold selectivity
forα1-GABAA receptors). It is of interest that none of the novel ligands
had a relatively high afﬁnity for the α1-containing receptors (once
more, the highest α1-subtype afﬁnity, the Ki of 22 nM, was possessed
by JY-XHe-053).3.2. Electrophysiological experiments
The in vitro concentration–effect curves for the four novel ligands,
in parallel with those for zolpidem and diazepam, are presented in
Fig. 1, together with explicit data on percent potentiation of a within-
and between-day stable EC3 GABA response at rat recombinant GABAA
receptors. The efﬁcacy data for SH-053-2′N and JY-XHe-053 have been
recently published (Rivas et al., 2009), and all data are shown here
together for comparison purposes. All four novel ligands exerted the
lowest positive modulation at α1-containing subtypes of receptors
relative to efﬁcacy at the other subtypes. In regard to the other three
receptor subtypes, the greatest separation of activity was noticed with
SH-053-R-CH3-2′F, which shows relatively low efﬁcacies atα2 andα3,
in addition to the α1-containing GABAA receptors. The other ligands
exerted substantial potentiation of an EC3 GABA response at α2 and
α3-containing receptors. At 100 nM concentration, which lies well in
the range of typical brain levels of BZ site ligands achievable in vivo
(cf. Pike et al., 2007; Wang et al., 2003), this potentiation was slightly
above (SH-053-2′N and JY-XHe-053) or slightly below (SH-053-S-
CH3-2′F) that one elicited through the α5-containing subtypes.
3.3. Motor activity assay
In the experiment with 1.25 and 2.5 mg/kg diazepam and 30mg/kg
SH-053-2′N, ANOVA showed a signiﬁcant effect of treatment on total
distance travelled during 45 min of monitoring (F(3,27)=8.33,
pb0.001) (Fig. 2, graph a1). According to Dunnett's test, the activity-
depressing effect of all three treatments was signiﬁcant compared with
solvent control. The effect wasmore pronounced in the peripheral zone
(F(3,27)=8.56, pb0.001), than in the central zone (F(3,27)=4.11,
p=0.016). When the analysis of distance travelled was developed into
5-min bins (Fig. 2, graph b1), it turned out that hypolocomotion was
signiﬁcant during the ﬁrst 20 min ofmonitoring, and again in the period
30–35 min, the effect of 30 mg/kg SH-053-2′N being somewhere in the
middle between the effects of two tested doses of diazepam.
Thedose response studywith JY-XHe-053 showeda signiﬁcanteffect
on total locomotor activity during 30 min of recording (F(5,36)=2.85,
p=0.029) (Fig. 2, graph a2). The effective doses of JY-XHe-053 were
10 and 40 mg/kg. The effect on central zone activitywas not discernible,
while statistical analysis of peripheral zone distance revealed that the
three higher doses of JY-XHe-053 were signiﬁcantly different from
control (not shown). The analysis of 5-min bins showed that during the
ﬁrst 5 min of recording the effect of JY-XHe-053 at 20 and 40mg/kgwas
signiﬁcant (Fig. 2, graph b2).
In the third experiment, an ANOVA for total distance was also
signiﬁcant (F(4,30)=4.50, p=0.006) (Fig. 2, graph a3). According to
Dunnett's test, 30 mg/kg SH-053-R-CH3-2′F, besides 2 mg/kg diaze-
pam, signiﬁcantly depressed locomotion. Notably, central zone
activity was affected more profoundly (F(4,30)=4.27, p=0.007)
than peripheral locomotion (F(4,30)=3.74, p=0.014), and SH-053-
R-CH3-2′F at 20 and 30 mg/kg decreased central, but not peripheral
Fig. 1. Concentration–effect curves for diazepam, zolpidem, SH-053-2′N, SH-053-S-CH3-2′F SH-053-R-CH3-2′F and JY-XHe-053 onα1β3γ2 (■),α2β3γ2 (▲),α3β3γ2 (♦), andα5β3γ2 (▼)
GABAA receptors, using an EC3 GABA concentration. Data points representmean±SEM from at least four oocytes from≥2 batches. As explained in the Results section, the efﬁcacy data for
SH-053-2′Nand JY-XHe-053hasbeenpublished inRivas et al. (2009). A concentrationof 100 nMofdiazepamresulted in246±16%, 400±22%, 461±34%, and322±7%of control current in
α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 GABAA receptors, respectively. A concentration of 100 nM of zolpidem resulted in 180±14%, 132±4%, 121±3%, and non-signiﬁcant changes
relative to control current inα1β3γ2,α2β3γ2,α3β3γ2, andα5β3γ2GABAA receptors, respectively. A concentration of 100 nMof SH-053-2′N resulted in 113±2%, 165±2%, 149±3%, and
130±3% of control current inα1β3γ2,α2β3γ2, α3β3γ2, and α5β3γ2 GABAA receptors, respectively. A concentration of 100 nM of SH-053-S-CH3-2′F resulted in non-signiﬁcant changes
relative to control current, 169±5%, 138±5%, and218±4%of control current inα1β3γ2,α2β3γ2,α3β3γ2, andα5β3γ2GABAA receptors, respectively. Theeffect of 1 μMof SH-053-S-CH3-
2′F at α1β3γ2 receptors was signiﬁcant relative to control (164±6%). A concentration of 100 nM of SH-053-R-CH3-2′F resulted in 111±2%, 124±9%, 125±8%, and 183±7% of control
current inα1β3γ2, α2β3γ2,α3β3γ2, and α5β3γ2 GABAA receptors, respectively. A concentration of 100 nM of JY-XHe-053 resulted in 169±10%, 307±14%, 345±26%, and 220±2% of
control current inα1β3γ2,α2β3γ2,α3β3γ2, andα5β3γ2GABAA receptors, respectively. All values givenwere signiﬁcantly different from the respective control currents (pb0.01, Student's
t-test).
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SH-053-R-CH3-2′F did not signiﬁcantly decrease locomotion in
neither of 6 intervals of recording, far different from diazepam
(2 mg/kg), which induced overt sedation during the ﬁrst 10 min of
recording.
Our recent study with SH-053-S-CH3-2′F at 30 mg/kg has shown a
signiﬁcant decrease of locomotor activity, which was signiﬁcantly
depressed in the time period 5–20 min, and only in the peripheral, but
not central, zone (Savić et al., 2008b).
3.4. Elevated plus maze
In regard to inﬂuence of SH-053-2′N on activity-related para-
meters (Fig. 3) in the plus maze, the overall effect of treatment did
not reach statistical signiﬁcance when closed arm entries (F(4,24)=
2.62, p=0.060) (Fig. 3a) and total distance travelled (F(4,24)=2.33,
p=0.085) (Fig. 3b) were analyzed. However, statistical analysis by
ANOVA showed a signiﬁcant effect of treatment on total arm entries
(F(4,24)=4.34, p=0.009). Dunnett's test revealed the signiﬁcant
effect of the two higher doses of SH-053-2′N in comparison to solvent
group (p=0.014 and 0.037, respectively) (Fig. 3c).
The inﬂuence of SH-053-2′N on anxiety-related parameters was
presented in Fig. 4. There was no signiﬁcant effect of treatment on
distance travelled in the open arms (F(4,24)=2.56, p=0.065)(Fig. 4a). Although the overall inﬂuence of treatment on the
percentage of open arm entries had reached statistical signiﬁcance
(F(4,24)=3.04, p=0.037) (Fig. 4b), neither of the single doses was
signiﬁcant on its own (post hoc test). The inﬂuence on the percentage
of time on open arms was signiﬁcant (F(4,24)=5.04, pb0.001)
(Fig. 4c), with diazepam and SH-053-2′N at 30 mg/kg as effective
treatments (p-values of 0.032 in both post hoc comparisons). Because
the parameter of total entries could not be seen as a relatively pure
index of locomotor activity, i.e. sedation (Cruz et al., 1994; Rodgers
and Johnson, 1995), an analysis of covariance in the anxiety-related
parameters using the number of total arm entries as covariate was not
necessary (cf. Savić et al., 2004). However, we opted to conduct a new
analysis of anxiety-related parameters, without data for diazepam as
positive control. This revealed the preserved signiﬁcance of effects of
SH-053-2′N on the percentage of open arm entries and the percentage
of time spent in open arms when an analysis of covariance was
performed using the number of closed arm entries as covariate
(respective F values: [F(3,18)=3.276, p=0.045)] and [F(3,18)=
6.027, p=0.005]). This indicates that the anxiolytic-like effects of SH-
053-2′N were not directly related with a trend of hypolocomotion in
rats treated with this ligand.
JY-XHe-053, administered in a wide range of doses, was devoid of
signiﬁcant behavioral activity in the elevated plus maze, when
analyzed both, general activity (data not shown) and anxiety-related
Fig. 2. The effects of diazepam (DZP 1.25 and 2.5 mg/kg) and SH-053-2′N 30 mg/kg (left graphs, a1 and b1), JY-XHe-053 (2.5, 5, 10, 20 and 40 mg/kg) (middle graphs, a2 and b2) and
DZP 2 mg/kg and SH-053-R-CH3-2′F (10, 20 and 30 mg/kg) (right graphs, a3 and b3) on distance travelled in the central (hatched bars) and peripheral (open bars) zone of the
activity chamber during 45 or 30 min of recording (total activity corresponds to the height of the whole bar) (upper graphs, a1, a2 and a3) as well as on distance travelled in 5-min
intervals (lower graphs, b1, b2 and b3). *, ** and ***, pb0.05; 0.01 and 0.001, respectively, compared to solvent (SOL) group in each of three experiments. Numbers of animals per
treatment, for consecutive groups on each of panels, were 8, 8, 7, 8 (left); 8, 6, 6, 8, 8, 6 (middle) and 7, 5, 7, 8, 8 (right).
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three anxiety-related parameters: distance in open arms (Fig. 5a),
percent of open arm entries (Fig. 5b) and percent of time spent on
open arms (Fig. 5c). Despite a hint of an inverted U-shape activity and
behavioral disinhibition at 5 mg/kg, discernible changes of behavior
were lacking.
The SH-053-R-CH3-2′F in doses up to 30 mg/kg was completely
devoid of changes of general activity- or anxiety-related parameters
in the elevated plus maze, and hence this set of data was not
presented.
Our recent study with SH-053-S-CH3-2′F has shown a signiﬁcant
effect of the 30 mg/kg dose on the percentage of open arm entries and
the percentage of time on open arms, without concomitant effects on
general activity-related parameters (Savić et al., 2008b).
3.5. Morris water maze
For the dose response study of zolpidem, the factors, treatment and
days, but not the interaction treatment×days, were statistically highly
signiﬁcant for the latency to ﬁnd the platform (treatment effect, F
(3,124)=21.01, pb0.001; day effect, F(4,496)=42.87, pb0.001; and
treatment×day interaction, F(12,496)=1.31, p=0.209) (shown in
Fig. 6a), the distance swum before ﬁnding the platform (treatment
effect, F(3,124)=4.71, p=0.004; day effect, F(4,496)=32.48,
p b0.001; and treatment×day interaction, F(12,496)=1.21,
p=0.270), average swim speed (treatment effect, F(3,124)=18.08,
pb0.001; day effect, F(4,496)=10.95, pb0.001; and treatment×day
interaction, F(12,496)=1.57, p=0.097) and path efﬁciency (treatment
effect, F(3,124)=7.75, pb0.001; day effect, F(4,496)=23.68, pb0.001;
and treatment×day interaction, F(12,496)=1.68, p=0.067). It is
worth noting that maximum speed was also signiﬁcantly different
among treatments, but in such a counterintuitive way that zolpidem-
treated animals tended to swim the faster (in themaximum) the higherthe dose of zolpidem was applied (data not shown). Signiﬁcant
differences among treatments during training days, obtained by one-
wayANOVAapplied to that day's latency toﬁndplatform, are presented
in Fig. 6a. The results of the post hoc analysis of overall inﬂuences for the
factor treatment are summarized in Table 2. The analysis showed that
the lowest tested dose of zolpidem, 0.5 mg/kg, was different related to
control, but also that rats treated with higher doses of the drug (1 and
2 mg/kg) were behaviorally impaired related to 0.5 mg/kg zolpidem.
The results of the probe trial showed an unexpected inconsistency
in the data from the control group. Hence, it was decided to perform
statistical analysis with zolpidem on its own (Table 3). The
incapacitating inﬂuences of the previous treatment with zolpidem
were discernible during the probe trial as well, when a number of
indices of memory were dose-dependently adversely affected
(number of entries in platform zone close to signiﬁcantly, time in
the target region signiﬁcantly). Concomitantly, a signiﬁcant increase
in the peripheral ring distance, i.e. pronounced thygmotaxis, has
shown that zolpidem impaired learning the required water-maze
skills and strategies.
In regard to the two other experiments in the water maze, the
results were generally dissimilar in relation to those obtained with
zolpidem. In the experiment with SH-053-S-CH3-2′F, SH-053-R-
CH3-2′F and SH-053-2′N, all dosed at 30 mg/kg, only the factor days,
but not the treatment or the interaction treatment×days, was
statistically signiﬁcant for the latency to ﬁnd the platform (treatment
effect, F(3,124)=1.40, p=0.248; day effect, F(4,496)=54.45,
p b0.001; and treatment×day interaction, F(12,496)=0.84,
p=0.611), the distance swum before ﬁnding the platform (treat-
ment effect, F(3,124)=0.95, p=0.419; day effect, F(4,496)=41.92,
p b0.001; and treatment×day interaction, F(12,496)=0.44,
p=0.947), swim speed (treatment effect, F(3,124)=2.24,
p=0.087; day effect, F(4,496)=9.13, pb0.001; and treatment×day
interaction, F(12,496)=0.96, p=0.489) and path efﬁciency (treatment
Fig. 4. The effects of diazepam (2.0 mg/kg) and SH-053-2′N (10, 20 and 30 mg/kg) on the
a)distance travelledonopenarms, b)percentage of entries inopenarms andc)percentage
of time spent on open arms of the EPM. *pb0.05 compared to solvent (SOL) group.
Fig. 3. The effects of diazepam (DZP 2.0 mg/kg) and SH-053-2′N (10, 20 and 30 mg/kg)
on the a) closed arm entries, b) total arm entries and c) total distance travelled in the
EPM. *pb0.05 compared to solvent (SOL) group. Number of animals per treatment
(Figs. 3 and 4, for SOL through SH-053-2′N 30 mg/kg, respectively): 6, 6, 5, 6, 6.
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and treatment×day interaction, F(12,496)=1.31, p=0.207). Similar
results were obtained for the latency to ﬁnd the platform (treatment
effect, F(3,108)=0.45, p=0.718; day effect, F(4,432)=90.88,
p b0.001; and treatment×day interaction, F(12,432)=1.03,
p=0.417), the distance swum before ﬁnding the platform (treatment
effect, F(3,108)=0.32, p=0.812; day effect, F(4,432)=56.12,
p b0.001; and treatment×day interaction, F(12,432)=1.64,
p=0.079), swim speed (treatment effect, F(3,108)=1.13, p=0.340;
day effect, F(4,432)=7.50, pb0.001; and treatment×day interaction,
F(12,432)=1.11, p=0.347) and path efﬁciency (treatment effect,
F(3,108)=0.90, p=0.445; day effect, F(4,432)=28.58, pb0.001; and
treatment×day interaction, F(12,432)=1.44, p=0.144) of rats treated
with JY-XHe-053 in the 5 to 40 mg/kg dose range. The graphs
representative of the latter two experiments, with latency to ﬁnd the
platform, are given in Fig. 6b and c, respectively. The one-way ANOVA
applied to latency to ﬁnd the platform showed a signiﬁcantly longer
search time on the fourth day in rats treated with 30 mg/kg SH-053-2′N
in comparison with control animals or those treated with 30 mg/kg SH-
053-S-CH3-2′F (Fig. 6b). However, this result should be seen as an
isolated case, since other learning parameters, such as path efﬁciency
presented in Fig. 7a, were not affected by SH-053-2′N on either of the
learning days. Furthermore, probe trial parameters were close to control
throughout the water-maze experiments performed with the newly-synthesized ligands. The lack of incapacitating consequences of the
previousﬁve-day treatmentwith SH-053-S-CH3-2′F, SH-053-R-CH3-2′F
and SH-053-2′N is illustrated in Fig. 7b, with the parameter of platform
zone entries during the probe trial presented.
In Fig. 8, the distances the rats swam in the platform quadrant (NE)
during acquisition trials are presented alongside the respective
distance in the portion of NE quadrant lying in the platform annulus
of the maze (“the target region”), for the chosen treatments from
three experiments. Providing the rats have no preference for any part
of a quadrant, the chance percent of distance swam in the target
region would be 40%. The inﬂuence of four novel ligands tested at
relatively high doses on this parameter was comparable to control
values. On the contrary, the rats treated with 2 mg/kg zolpidem
strikingly lacked the preferential activity in that part of the NE
quadrant in which ﬁnding the platform was possible; even on day 5,
only 40.5% of the overall distance they travelled in the NE quadrant
was in the target region.
4. Discussion
A substantial body of evidence from both, genetic (reviewed in
Rudolph and Möhler, 2006) and pharmacological studies (e.g. Savić
et al., 2009), supports the search for a new generation of positive
allosteric modulators at GABAA receptors, which would mostly be
Fig. 5. The inﬂuence of JY-XHe-053 (0; 2.5; 5; 10; 20 and 40 mg/kg) on the a) distance
travelled on open arms, b) percentage of entries in open arms and c) percentage of time
spent on open arms of the EPM. Number of animals per treatment (for SOL through JY-
XHe-053 40 mg/kg) was 7.
Fig. 6. The effects of a) zolpidem (ZOL 0.5, 1 and 2 mg/kg), b) SH-053-2′N, SH-053-S-
CH3-2′F and SH-053-R-CH3-2′F (all dosed at 30 mg/kg) and c) JY-XHe-053 (5; 20 and
40 mg/kg), on latency to platform. *, ** and ***, pb0.05; 0.01 and 0.001, respectively,
compared to solvent (SOL) group in each of three experiments. In graph a): +,++, and
+++, pb0.05; 0.01 and 0.001, respectively compared to ZOL 0.5 group; #, pb0.05
compared to ZOL 1.0 group; ∧ and ∧∧, pb0.05 and 0.01, ZOL 1 group compared to ZOL
0.5 group. In graph b): ++, pb0.01 compared to SH-053-S-CH3-2′F 30group. Number
of animals per each treatment was 8 in a) and b), and 7 in c).
Table 2
Signiﬁcant differences among overall inﬂuences (averaged for ﬁve days of acquisition)
on the water-maze learning parameters: latency to ﬁnd the platform (L), distance
swam before ﬁnding the platform (D), mean swim speed (S) and path efﬁciency (E) in
the dose response study of zolpidem (ZOL, mg/kg).
ZOL 0.5 ZOL 1 ZOL 2
Solvent L: p=0.009 L: pb0.001 L: pb0.001
S: p=0.009 D: p=0.010 D: p=0.004
E: p=0.010 S: pb0.001 S: pb0.001
E: pb0.001 E: pb0.001
ZOL 0.5 – L: p=0.018 L: pb0.001
S: p=0.011 S: pb0.001
ZOL 1 – – L: p=0.014
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receptors which contain the α1 subunit are believed to be responsible
for most of the untoward effects of BZs, and silencing the activity at
this subunit has appeared as the most attractive approach (Whiting,
2006). The present experiments focused on the recently synthesized
ligands: SH-053-2′N, SH-053-S-CH3-2′F, SH-053-R-CH3-2′F and JY-
XHe-053, which as a common trait have moderately low to low
afﬁnity and mild to partial agonistic efﬁcacy at α1-containing GABAA
receptors. Positive efﬁcacy is more pronounced at the other BZ-
sensitive binding sites in comparison to the α1-subtype. Putting aside
for the moment the subtle differences in the in vitro and in vivo
pharmacology of novel ligands, it was observed that evenwith ligands
that demonstrated efﬁcacy “lower at the α1 subtypes than at the rest
of the subunits”, the sedative-like potential of such GABAAmodulation
was not fully eliminated, while the spatial learning and memory
impairments, assessed in the water maze and usually seen with BZ
site agonists, were completely circumvented; the latter ﬁnding
represents the single most important result from the present study.
The decreased locomotion induced by all four novel ligands (the
effect of 30 mg/kg SH-053-S-CH3-2′F was presented in Savić et al.,
2008b) which were tested may be rationalized in two ways. Firstly,although the lack of occupancy (in vivo potency) data for distinct
receptor subtypes precludes drawing ﬁrm conclusions about the
actual activity at α1-containing GABAA receptors, which are predom-
inantly involved in sedative actions of BZs according to genetic
(Rudolph et al., 1999) and pharmacological antagonism studies (Savić
et al., 2009), it cannot be excluded that, even at presumably low
fractional occupancy, moderately low to moderate positive modula-
tion (partial agonism) at these α1-receptors may be sufﬁcient for
eliciting weak sedation (cf. Grimwood and Hartig, 2009). Secondly,
growing neuroanatomical evidence points to the possible role of α5-
containing GABAA receptors in motor control (Bohlhalter et al., 1996;
Pirker et al., 2000; Yamada et al., 2007), and we recently suggested
that any locomotor activity changes induced by ligands possessing a
Table 3
The representative parameters of water-maze performance in the probe trial of the
zolpidem (ZOL) dose response experiment. The key to regions used in the analysis is
given in Fig. 1.
ZOL 0.5 ZOL 1.0 ZOL 2.0 ANOVA,
F(2,21)
p
Whole water-maze parameters
Distance (m±SEM) 10.93±0.97 11.50±0.96 12.75±0.56 1.187 0.325
Platform quadrant (NE) parameters
Distance (m±SEM) 2.41±0.29 2.18±0.51 2.22±0.44 0.083 0.920
Time (s±SEM) 11.86±1.44 9.64±1.92 9.75±2.06 0.471 0.631
Peripheral ring parameters
Distance (m±SEM) 4.16±0.61 6.09±0.89 7.85±0.82⁎ 5.564 0.012
Time (s±SEM) 33.48±3.68 39.86±1.67 42.80±3.35 2.473 0.109
Platform ring parameters
Distance (m±SEM) 5.27±0.68 4.48±0.31 4.00±0.65 1.247 0.308
Time (s±SEM) 21.46±3.05 17.31±1.38 14.50±2.60 2.049 0.154
Target region parameters
Distance (m±SEM) 1.51±0.27 1.12±0.14 0.99±0.22 1.520 0.242
Time (s±SEM) 7.26±1.36 4.03±0.52⁎ 3.51±0.76⁎ 4.596 0.022
Platform parameters
Number of entries
(±SEM)
1.25±0.41 0.38±0.18 0.50±0.19 2.813 0.083
Distance (m±SEM) 0.097±0.031 0.047±0.028 0.053±0.023 0.945 0.405
*, pb0.05 compared to ZOL 0.5 group.
Fig. 7. The effects of SH-053-2′N, SH-053-S-CH3-2′F and SH-053-R-CH3-2′F, all dosed at
30 mg/kg, on a) path efﬁciency during 5-day acquisition sessions and b) number of
entries to the zone of previous days' position of platform in probe trial.
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GABAA receptors containing this subunit (Savić et al., 2008b). GABAA
receptors containing the α5-subunit are functionally interrelated in
some manner with those containing the α1-subunit. Importantly,
knock-in mice harboring the α5 subunit insensitive to diazepam are
refractory to the development of tolerance to the sedative effects of
diazepam dosed subchronically (van Rijnsoever et al., 2004). Moreover,
the α5-selective antagonist XLi093, at a dose presumably causing a
complete antagonismof the effects of diazepamatα5-containingGABAA
receptors, has potentiated sedation induced by diazepam (Savić et al.,2009). Hence, we further hypothesized that positive modulation at α5
GABAA receptors may exert a dual action: to limit sedative effects
elicited by supra-physiological stimulation of α1-containing receptors
(e.g. by full agonists), and, oppositely, to enhance low activation of α1
GABAA receptors (e.g. by partial agonists), and, hence, induce mild
sedation (Savić et al., 2009). Such a modulation might be achieved if
neurons involved in sedative actions are modulated strongly by α1 as
well as more weakly by α5 receptors, and if the synapse or neuron
mediating theα1modulation is at the same timeweakly regulated byα5
receptors. Then lowactivity atα1 receptors canoverall be enhanced by a
direct α5 receptor activity on the same neuron, but strong α5 activity
would downregulate the strong sedative action of α1 activity via its
indirect effect on the synapse or neuron mediating the α1 modulation.
Such a scenario could, at least partly, explain the unexpected ﬁnding
that the mice lacking the α1-containing GABAA receptors were more
sensitive to hypolocomotion and loss of righting reﬂex induced by
diazepam, compared to wild-type controls (Kralic et al., 2002).
The differences in the capability to induce anxiolytic effects, ob-
served with the ligands evaluated here, are not easily reconciled.
Genetic studies have indicated that the α2 subunit was predominantly
involved in the anxiolytic-like effects of positive modulation at GABAA
receptors (Low et al., 2000), while results with some novel selective
ligands pointed to the role of the α3 subunit, as well (Dias et al., 2005).
The ligand SH-053-R-CH3-2′F was devoid of anxiolytic potential, in line
with results of a congener with a similar proﬁle of α5 GABAA functional
selectivity, SH-053-R-CH3 (Savić et al., 2008b). However, JY-HXe-053, a
ligandwith relatively high afﬁnity and efﬁcacy atα2 and α3-containing
GABAA receptors, was devoid of discernible anxiolytic activity, too.
When comparing this result with the anxiolytic-like properties of SH-
053-2′N and SH-053-S-CH3-2′F (the latter is published in Savić et al.,
2008b), it was found that JY-HXe-053 has a greater afﬁnity at α1-, and
especiallyα5-containingGABAA receptors,with substantial potentiation
at these receptors achieved already at concentration of 100 nM (169%
and 220%, respectively). Since JY-HXe-053 has induced a hypolocomo-
tor effect in the SLA at doses (10 mg/kg and above) lower than those
observed with SH-053-2′N or SH-053-S-CH3-2′F (30 mg/kg), it is
possible that its activity at α1 and, in parallel, α5 receptors may have
masked the expected anxiolytic-like effects mediated by the other two,
α2 and α3-containing, subtypes of GABAA receptors. When one
compares the in vitro proﬁle of JY-XHe-053 with that of diazepam, it
is clear that JY-XHe-053, but not diazepam, exhibits a preferential
afﬁnity for α5-GABAA receptors. The consequent ‘priority in activity’ at
α5-GABAA receptors may have endowed this population of receptors
with a relativelymore distinct role in inﬂuencing the overall behavior of
rats treated with JY-XHe-053, rather than with diazepam. Finally, it is
notable that the hypolocomotor inﬂuence of JY-XHe-053 in the SLA test
was evident only when analyzing activity in the peripheral, but not in
the central zone of the chamber, and could be seen as a puremeasure of
sedation (cf. Savić et al., 2006; 2008b). On the contrary, the
hypolocomotion induced by SH-053-R-CH3-2′F was due to the
inactivity in the central, but not the peripheral zone, which suggests
that the sedation-like actions exerted through α1 and α5 GABAA
receptors are qualitatively different.
We have previously shown that, when observable, the anxiolytic-
like effects of zolpidem, the preferential α1-subunit selective agonist
with intermediate activity at α2 and α3-containing GABAA receptors,
are statistically dependent on the concomitant decrease of closed arm
entries in the elevated plus maze, and hence confounded by general
activity changes (Savić et al., 2004). Analysis of covariance for the
current results with SH-053-2′N did not reveal analogous dependence
of its anxiolytic-like effects on the concomitant signs of sedation.
Nevertheless, it is possible the clinical separation of wanted anxiolytic
from unwanted sedative effects would be lower for SH-053-2′N than
for SH-053-S-CH3-2′F, having in mind that the latter ligand was
devoid of inﬂuence on the parameters related to general activity in the
elevated plus maze (cf. Savić et al., 2008b).
Fig. 8. The effects of b) zolpidem (ZOL 2), c) JY-XHe-053 30, d) SH-053-2′N 30, e) SH-053-R-CH3-2′F and f) SH-053-S-CH3-2′F 30 (all doses inmg/kg) on the distance rats travelled in
the NE quadrant and target region during 5-day acquisition trials in the water maze. The numbers inside the columns are the percent of the distance swam inside the target (NE)
quadrant which was travelled in the target region. Control values (SOL) given in a) are taken from the experiment with ZOL. Numbers of animals are as in Fig. 6.
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learning in the water maze have not been previously assessed.
Zolpidem dose-dependently impaired the declarative component of
both, learning the task, as assessed by path efﬁciency, the latency and
distance before ﬁnding the platform across acquisition trials, and
recalling the previous platform position, as assessed by time in the
target region during the probe trial. It also induced a decrease in
average swim speed, accompanied by increase in maximum swim
speed, whichmay be interpreted as ‘bursts’ of behavioral disinhibition
(activation) interspersed among background sedative effect. By the
use of the treatment switch, McNamara and Skelton (1991) have
shown that the reduced swim speed cannot account for deﬁcits in
platform localization induced by BZs. Namely, the rats acquiring the
task under saline treatment continued to perform normally despite
the switch to diazepam, which nonetheless elicited a decrease in
swim speed (McNamara and Skelton, 1991). Hence, the data suggest
that neither non-speciﬁc performance impairment, nor any sensori-
motor deﬁcit (according to our preliminary ﬁndings with zolpidem in
the task of ﬁnding the visible platform) was responsible for the
observed acquisition deﬁcit (cf. McNamara and Skelton, 1991).
Zolpidem also negatively affected the procedural component of the
water-maze task. Namely, suppression of an instinct to swim thigmo-
taxically appears to be necessary to effectively accomplish this task
(Cain, 1998), and zolpidemat 2 mg/kg induced an increase of peripheral
annulus, and a decrease of platform annulus parameters throughout the
test. We have recently shown that both, the α1-subunit afﬁnity-
selective antagonist ß-CCt, and the α5-subunit afﬁnity- and efﬁcacy-
selective antagonist XLi093, may, at least partially, prevent diazepam-
induced impairment in thedeclarativeandprocedural componentof thewater-maze task; however, the antagonistic effect of ß-CCt was
manifestly more profound (Savić et al., 2009). The present results
show,ﬁrst, that the effects of zolpidem, a ligandessentially inactive atα5
GABAA receptors, mirror those induced by diazepam, and secondly, that
three novel ligands, with moderately low to low activity at α1 GABAA
receptors, do not disturb water-maze behavior. The conclusion is
straightforward: a substantial amount of activity atα1 GABAA receptors
is needed if spatial learning andmemory incapacitation is to be induced
by positive allosteric modulation at BZ site. The positive modulation at
α5 GABAA receptors may add to the incapacitating action effected
through the α1 subunit, but is neither necessary (cf. zolpidem), nor
sufﬁcient (cf. SH-053-R-CH3-2′F) for spatial cognition impairment in
the water maze.
The present data and the above conclusions may thus signiﬁcantly
change the common knowledge on the function of individual receptor
subtypes (Rudolph and Möhler, 2006) and reﬂect a more realistic view
that more than one GABAA receptor subtype is modulating the same
behavioral parameter. We suggest a tentative hypothesis based on the
existence of the ﬁne equilibrium between the α1- and α5-GABAA
receptors on the one hand, and α2- and α3-GABAA receptors on the
other side, in terms of the inﬂuence of positive allosteric modulation on
the crucial behavioral endpoints of sedation, anxiolysis and amnesia. A
substantial amount of positive modulation is needed by the α1,
coordinated in some manner with α5-GABAA receptors, if sedation
and amnesia are to be elicited, while for the anxiolytic-like actions the
α2 and/or α3 GABAA receptors must be activated. The other pair of
receptors, not primarily involved in mediation of the respective
behavioral effect, may counteract, mask or in another way hinder the
action of the responsible pair.
386 M.M. Savić et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 34 (2010) 376–3865. Conclusions
Between the novel positive allosteric modulators presented in this
and the previous paper (Savić et al., 2008b), it appears that SH-053-S-
CH3-2′F may possess a pharmacological proﬁle appropriate for further
ﬁne tuning, by diminishing the potential of sedation, probably through
an additional decrease of activity at α1- and α5-GABAA receptors. A
future, more elaborate analysis of the substrate of behavioral effects of
BZ site modulators shall take into account target site occupancy,
quantitative neuroanatomical distribution of distinct receptor subtypes,
differences among animal species, receptor reserve (if any) of the
behavioral effect under investigation (cf. Grimwood and Hartig, 2009)
as well as different settings and methods of behavioral assessment.
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